drugset / Trial / NCT07576608
A Phase II Study of 9MW3811 in Patients With Pathological Scar
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of 9MW3811 in patients with pathological scar.
Timeline
- Start
- 2025-12-29
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 9MW3811 | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.